Diabetes requires lifelong management to prevent serious complications. Modern treatment spans insulin therapy, oral medications targeting different metabolic pathways, and intensive lifestyle modifications. Regenerative approaches are being studied as potential adjuncts to restore pancreatic function.
Type 1 diabetes demands insulin replacement through multiple daily injections or continuous infusion pumps, combined with frequent blood-glucose monitoring and carbohydrate counting. Type 2 management typically begins with metformin—a first-line biguanide that reduces hepatic glucose production. GLP-1 receptor agonists (semaglutide, dulaglutide) now feature prominently for both types, offering cardiovascular and weight-loss benefits. SGLT2 inhibitors improve kidney and heart outcomes. Sulfonylureas and meglitinides stimulate insulin secretion; DPP-4 inhibitors extend incretin activity. Thiazolidinediones enhance insulin sensitivity. Bariatric surgery may achieve remission in suitable candidates by reducing insulin resistance.
Dietary approaches—notably low-glycaemic-index foods, Mediterranean and DASH patterns—improve glycaemic control without medications. Chromium picolinate, cinnamon extracts, and inositol supplements show modest evidence in observational studies but lack robust RCT support. Acupuncture, herbal formulations (fenugreek, bitter melon), and yoga-based breathing may reduce glucose variability but are not replacements for conventional therapy.
Stem-cell therapies are being studied for pancreatic β-cell regeneration and immune tolerance in Type 1 diabetes. Mesenchymal stem cells may reduce inflammation and improve insulin secretion; clinical trials are ongoing in several countries. These approaches remain investigational and should not delay proven medications. See candidacy criteria for trial eligibility.
| Option | Type | Evidence | Indicative cost | Invasiveness | Recovery |
|---|---|---|---|---|---|
| Insulin therapy (basal-bolus or pump) | Standard | Strong | €1,200–2,400/year | Medium | None (routine management) |
| GLP-1 receptor agonist (semaglutide, dulaglutide) | Standard | Strong | €2,800–4,500/year | Low | None |
| SGLT2 inhibitor (dapagliflozin, empagliflozin) | Standard | Strong | €1,500–2,200/year | Low | None |
| Bariatric surgery (gastric bypass, sleeve) | Standard | Strong | €8,000–15,000 | High | 6–8 weeks |
| Chromium and herbal supplementation | Alternative | Limited | €50–150/year | Low | None |
| Pancreatic β-cell regeneration (stem-cell) | Regenerative | Investigational | €10,000–25,000 (trial-dependent) | Medium | 1–2 weeks |
| Mesenchymal stem-cell immunomodulation | Regenerative | Investigational | €12,000–28,000 (trial-dependent) | Medium | 1–2 weeks |
Stem-cell therapies show promise in early clinical trials for promoting β-cell regeneration and reducing autoimmune destruction in Type 1. However, they are not yet curative and remain investigational. All patients continue insulin and glucose monitoring during and after treatment.
Type 1 focuses on immune tolerance and β-cell preservation; Type 2 targets insulin-secretion enhancement and metabolic inflammation. Candidate selection differs significantly between the two.
Most trials report measurable changes in glucose control and C-peptide levels within 3–6 months. Benefits may continue improving over 12 months of follow-up.
We link primary regulators, registries and peer-reviewed research so you can verify everything yourself — plus the treating clinic's own materials.
Educational overview of treatment options; not medical advice. Standard treatments reflect mainstream guidance; regenerative/stem-cell uses are largely investigational. Reviewed by the StemCellAtlas editorial team.
位于欧盟核心的 GMP 认证再生医学诊所——费用 3,000–8,000 欧元起，仅为美国或德国价格的一小部分。为来自 50 多个国家的国际患者提供个性化方案。
免费医疗评估